Discovery of a Novel Potent Inhibitor of HIV Infection
A number of agents active against the human immunodeficiency virus (HIV) currently are under consideration for clinical use in AIDS. Nonetheless, the only drugs exhibiting unequivocal clinical efficacy are those which inhibit the activity of viral reverse transcriptase, specifically certain dideoxynucleosides including azidothymidine (AZT)(1), dideoxycytidine (DDC)(2), and dideoxyinosine (3). The failure to effect a complete cure of the disease with dideoxynucleosides, the toxicities associated with longterm treatments with these compounds (2,4), and the occurrence of AZT-resistant mutants (5), are considerations which necessitate the discovery and development of new drugs effective against AIDS.
KeywordsHuman Immunodeficiency Virus Thionyl Chloride Human Immunodeficiency Virus Protease Chlorobenzoic Acid Human Immunodeficiency Virus Reverse Transcriptase
Unable to display preview. Download preview PDF.
- 1.Yarchoan R, Kelecker RW, Weinhold KJ, Markham PD, Lyerly HK, Durack DT, Gelmann E, Lehrman SN, Blum RM, Barry DW, Shearer GM, Fischi MA, Mitsuya H, Gallo RC, Collins JM, Bolognesi DP, Myers CE, Broder, S. Administration of 3’ -azido-3’ -deoxythymidine, an inhibitor of HTLVIII/LAV replication, to patients with AIDS or AIDS-related complex. Lancet 1986; 1: 575–80.PubMedCrossRefGoogle Scholar
- 2.Yarchoan R, Perno CF, Thomas RV, Klecker RW, Allain JP, Wills RJ, McAtee N, Fischl MA, Dubinsky R, McNeely MC, Mitsuya H, Pluda JM, Lawley TJ, Leuther M, Safai B, Collins JM, Myers CE, Broder S. Phase I studies of 2’,3’ -dideoxycytidine in severe human immunodeficiency virus infection as a single agent and alternating with zidovudine (AZT). Lancet 1988; 1: 76–81.PubMedCrossRefGoogle Scholar
- 6.Boyd MR. Strategies for the identification of new agents for the treatment of AIDS: A national program to facilitate the discovery and preclinical development of new drug candidates for clinical evaluation. In Devita VT Jr, Hellman S, Rosenberg SA, eds. AIDS Etiology, Diagnosis, Treatment and Prevention. Philadelphia: Lipencott 1988, 305–317.Google Scholar
- 8.Bader J, McMahon J, Schultz R, Narayanan V, Boyd M. Oxathiin carboxanilide: A novel potent inhibitor of HIV reproduction. Third Int Conf on Antiviral Research, April 22–27, 1990.Google Scholar
- 9.Midelfort F, Schultz R, Narayanan V, Weislow O, McMahon J, Bader J, Boyd M. AIDS antiviral activity of oxathiin benzoic acid ester (NSC 615985). Sixth Int Conf on AIDS, San Francisco, June 243, 20–24, 1990.Google Scholar
- 10.Harrison WA, Kulka M, Thiara DS, von Schemeling B. US Patent 3, 249, 499, 1966.Google Scholar
- 11.Bader JP, McMahon JB, Schultz RJ, Narayanan VL, Pierce JB, Harrison WA, Weislow OS, Midelfort CF, Stinson SF, Boyd MR. Oxathiin carboxanilide, A potent inhibitor of human immunodeficiency virus reproduction. Submitted for publication.Google Scholar
- 13.Matsukura M, Zon G, Shinozuka K, Robert-Guroff M, Shimada T, Stein CA, Mitsuya H, Wong-Staal F, Cohen JS, Broder S. Regulation of viral expression of human immunodeficiency virus in vitro by an antisense phosphorothioate oligodeoxynucleotide against rev (art/trs) in chronically infected cells. Proc Natl Acad Sci USA 1989; 86: 4244–8.PubMedCrossRefGoogle Scholar